Mereo Biopharma Group Plc ADR (NASDAQ:MREO)’s traded shares stood at 0.91 million during the latest session, with the company’s beta value hitting 0.77. At the last check today, the stock’s price was $3.35, to imply an increase of 11.50% or $0.35 in intraday trading. The MREO share’s 52-week high remains $4.36, putting it -30.15% down since that peak but still an impressive 79.4% since price per share fell to its 52-week low of $0.69. The company has a valuation of $429.46M, with an average of 1.11 million shares in intraday trading volume over the past 10 days and average of 1.75 million shares over the past 3 months.
Mereo Biopharma Group Plc ADR (NASDAQ:MREO) trade information
After registering a 11.50% upside in the latest session, Mereo Biopharma Group Plc ADR (MREO) has traded red over the past five days. The stock hit a weekly high of 3.45, jumping 11.50% in its intraday price action. The 5-day price performance for the stock is 13.01%, and -10.32% over 30 days. With these gigs, the year-to-date price performance is 44.81%. Short interest in Mereo Biopharma Group Plc ADR (NASDAQ:MREO) saw shorts transact 2.19 million shares and set a 1.46 days time to cover.
Mereo Biopharma Group Plc ADR (MREO) estimates and forecasts
Looking at statistics comparing Mereo Biopharma Group Plc ADR share performance against respective industry, we note that the company has outperformed competitors. Mereo Biopharma Group Plc ADR (MREO) shares are 148.70% up over the last 6 months, with its year-to-date growth rate higher than industry average at 110.00% against 12.70%.
MREO Dividends
Mereo Biopharma Group Plc ADR has its next earnings report out between March 29 and April 02. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. Mereo Biopharma Group Plc ADR has a forward dividend ratio of 0, with the share yield ticking at 0.00% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.
Mereo Biopharma Group Plc ADR (NASDAQ:MREO)’s Major holders
Mereo Biopharma Group Plc ADR insiders hold 0.51% of total outstanding shares, with institutional holders owning 61.41% of the shares at 61.73% float percentage. In total, 61.41% institutions holds shares in the company, led by Rubric Capital Management LP. As of Dec 30, 2023, the company held over 13.55 million shares (or 20.01% of shares), all amounting to roughly $46.35 million.
The next major institution holding the largest number of shares is Soleus Capital Management, L.P. with 9.78 million shares, or about 14.43% of shares outstanding. As of the market price on Dec 30, 2023, these shares were worth $33.44 million.
We also have abrdn Healthcare Investors and abrdn Life Sciences Investors as the top two Mutual Funds with the largest holdings of the Mereo Biopharma Group Plc ADR (MREO) shares. Going by data provided on Dec 30, 2023, abrdn Healthcare Investors holds roughly 1.06 million shares. This is just over 1.57% of the total shares, with a market valuation of $3.64 million. Data from the same date shows that the other fund manager holds a little less at 0.49 million, or 0.72% of the shares, all valued at about 1.67 million.
